

Evaluation of the SENS-U as an alarm intervention in the treatment of children with daytime urinary incontinence

Submission date 04/01/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 23/03/2022	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 20/10/2023	Condition category Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Urotherapy is the first treatment of choice for functional daytime urinary incontinence (DUI) in children. Alarm therapy can be a part of urotherapy as it provides the child adequate feedback on wetting accidents. Current alarm systems notify either at a set interval or give a notification when wetting has already occurred to prompt the child to go to the toilet. These alarms do not teach the child the interpretation of the bladder sensation preceding wetting accidents. A new wearable bladder sensor, the SENS-U, recently became available. This is a small, wireless ultrasonic sensor, which continuously monitors bladder filling. The SENS-U is able to provide an alarm at the exact moment voiding is warranted. It facilitates the child to learn the sensation of bladder filling preceding voiding in an easier way, increasing the learning curve throughout treatment.

The aim of this multicenter single-blinded randomized controlled trial is to assess the additional effect of continuous ultrasound bladder monitoring in urotherapy for children with functional daytime urinary incontinence.

Who can participate?

Children aged 6 to 16 years old with functional daytime urinary incontinence.

What does the study involve?

Participants will be divided into three groups at random, with each participant having an equal chance of being in each group. Participants will receive either urotherapy only for 3 months, urotherapy for 3 months with 3 consecutive weeks using the SENS-U device, or urotherapy for 3 months with 3 consecutive weeks with the using a sham device.

What are the possible benefits and risks of participating?

By training, subjects might benefit from treatment by reduction in wetting accidents. Potential risks are discomfort or redness of the skin while wearing the device.

Where is the study run from?
Radboud UMC (Netherlands)

When is the study starting and how long is it expected to run for?
From June 2021 to June 2026

Who is funding the study?
ZonMw (Netherlands) and Novioscan (Netherlands)

Who is the main contact?
Eline van de Wetering, Eline.vandewetering@radboudumc.nl

Study website
www.de-sensu-studie.nl

Contact information

Type(s)
Scientific

Contact name
Mrs Liesbeth de Wall

ORCID ID
<http://orcid.org/0000-0002-1704-6772>

Contact details
Geert Grooteplein Zuid 10
Nijmegen
Netherlands
6525 GA
+31 (0)24 361 3735
secretariaat.uro@radboudumc.nl

Type(s)
Public

Contact name
Mrs Eline van de Wetering

ORCID ID
<http://orcid.org/0000-0002-9144-1375>

Contact details
Geert Grooteplein Zuid 10
Nijmegen
Netherlands
6525 GA
+31615188436
Eline.vandewetering@radboudumc.nl

Type(s)

Scientific

Contact name

Mrs Anka Nieuwhof-Leppink

ORCID ID

<http://orcid.org/0000-0002-2841-813X>

Contact details

Lundlaan 6

Utrecht

Netherlands

3584 EA

+31887554111

a.nieuwhof-leppink@umcutrecht.nl

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number**ClinicalTrials.gov number**

Nil known

Secondary identifying numbers

80-85200-98-21037

Study information

Scientific Title

The SENS-U trial: evaluation of the additional effect of continuous ultrasound bladder monitoring in urotherapy for children with functional daytime urinary incontinence

Acronym

SENS-U

Study objectives

Urotherapy combined with the SENS-U reduces the number of wetting accidents per week in children with functional daytime urinary incontinence

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 04/01/2022, METC Oost-Nederland (Philips van Leydenlaan 25, 6500 HB Nijmegen; +31 (0)24 3613154; commissiemensgebondenonderzoek@radboudumc.nl), ref: 2021-13134, NL number: NL78403.091.21

Study design

Multicenter interventional single-blinded randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

www.de-sensu-studie.nl

Health condition(s) or problem(s) studied

Treatment of children with functional daytime urinary incontinence

Interventions

Participants will be divided into 3 arms in a 1:1:1 fashion:

1. Urotherapy only (control group)
2. Urotherapy + SENS-U
3. Urotherapy + Sham-device (placebo)

Urotherapy will be given for 3 months. Children who are placed in the SENS-U or Sham-device arm will wear the device for 3 consecutive weeks during the 3 months of urotherapy treatment.

The SHAM-device has the exact same appearance as the SENS-U. However, it does not measure the filling state of the bladder. The SHAM-device is programmed to give an alarm at set time intervals. The device can best be compared to alarm interventions such as the timer watch.

Outcome parameters will be measured at baseline, after the end of 3-weeks intensive training with diary, after 3 months, and at 6 months after starting training.

Intervention Type

Device

Phase

Phase III/IV

Drug/device/biological/vaccine name(s)

SENS-U Sham-device (placebo)

Primary outcome measure

Number of 'wetting accidents' per week measured by questionnaires at baseline and 3 months

Secondary outcome measures

1. Subjective improvement of LUTS according to parents using questionnaires at baseline, 3, and 6 months
2. Change in urinary incontinence during follow-up measured using the number of wetting accidents per week at 6 months
3. Change in frequency voiding chart parameters (average, minimum, maximum void volumes corrected for bladder capacity for age (EBC) measured using voiding charts at baseline, 3, and 6 months
4. Change in Quality of Life measured using questionnaires at baseline, 3, and 6 months
5. Cost-effectiveness measured using questionnaires set out to costs at 6 months
6. Magnitude of the placebo-effect measured using number of wetting accidents per week at baseline and 3 months

Overall study start date

08/06/2021

Completion date

08/06/2026

Eligibility

Key inclusion criteria

1. Aged between 6 and 15 years
2. Functional daytime urinary incontinence
3. Diagnosed with overactive bladder, dysfunctional voiding, or underactive bladder according to ICCS criteria
4. Eligible for urotherapy

Participant type(s)

Patient

Age group

Child

Lower age limit

6 Years

Upper age limit

15 Years

Sex

Both

Target number of participants

480

Key exclusion criteria

1. History of congenital urogenital anomalies except for successfully treated mild infravesical obstruction
2. History of neurological underlying disease

3. History of botox treatment for lower urinary tract dysfunction (LUTD)
4. Untreated or treated but persisting functional constipation according to Rome IV criteria <6 months before inclusion
5. Recurrent culture-proven urinary tract infection (UTI) <3 months before inclusion or not controlled by prophylactic antibiotics
6. Previous urotherapy/bladder training <6 months before inclusion
7. Adipositas preventing accurate measurement by the SENS-U as defined as a BMI >95th percentile according to age/gender
8. Skin problems in suprapubic area that are incompatible with the SENS-U adhesive
9. Developmental and intellectual disabilities or severe behavioural and social problems that are incompatible with protocolled urotherapy treatment based on the history and on the opinion of the clinician/urotherapist

Date of first enrolment

01/02/2022

Date of final enrolment

01/04/2024

Locations

Countries of recruitment

Netherlands

Study participating centre

Radboudumc

Geert Grooteplein Zuid 10

Nijmegen

Netherlands

6525 GA

Study participating centre

UMC Utrecht, Wilhelmina Kinderziekenhuis

Lundlaan 6

Utrecht

Netherlands

3584 EA

Study participating centre

TOP voor Kinderen

De Hooie Bongert 1

Zevenaar

Netherlands

6903 DA

Study participating centre**Isala**

Dokter van Heesweg 2

Zwolle

Netherlands

8025 AB

Study participating centre**Ziekenhuis Gelderse Vallei**

Willy Brandtlaan 10

Ede

Netherlands

6716 RP

Sponsor information

Organisation

Radboud University Nijmegen Medical Centre

Sponsor details

Geert Grooteplein Zuid 10

Nijmegen

Netherlands

6525

+31243611111

Eline.vandewetering@radboudumc.nl

Sponsor type

Hospital/treatment centre

Website

<https://www.radboudumc.nl/EN/Pages/default.aspx>

ROR

<https://ror.org/05wg1m734>

Funder(s)

Funder type

Research organisation

Funder Name

ZonMw

Alternative Name(s)

Netherlands Organisation for Health Research and Development

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

Netherlands

Funder Name

Novioscan

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

31/12/2025

Individual participant data (IPD) sharing plan

Pseudonymized individual participant data is stored and analyzed in anDREA during the study. At the end of the study, all generated data will be stored in a proprietary format in the DANS EASY repository. In order to reproduce the study findings and to help future users to understand and reuse the data, all changes made to the raw data, including analysis steps will be documented in a data management plan.

IPD sharing plan summary

Stored in publicly available repository

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article		13/08/2022	15/08/2022	Yes	No